4.6 Review Book Chapter

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

期刊

ANNUAL REVIEW OF IMMUNOLOGY, VOL 28
卷 28, 期 -, 页码 57-78

出版社

ANNUAL REVIEWS
DOI: 10.1146/annurev-immunol-030409-101243

关键词

OX40L; costimulation; T cells; autoimmunity; infectious disease; vaccination

资金

  1. NCI NIH HHS [CA91837, R01 CA091837, R01 CA091837-07] Funding Source: Medline
  2. NIAID NIH HHS [R56 AI067341, R01 AI067341, AI49453, U19 AI070535-040003, R01 AI067341-04, AI070535, R01 AI049453-08, U19 AI070535, R01 AI049453, AI67341] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA091837] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI067341, R01AI067341, U19AI070535, R01AI049453] Funding Source: NIH RePORTER

向作者/读者索取更多资源

TNFR/TNF superfamily members can control diverse aspects of immune function. Research over the past 10 years has shown that one of the most important and prominent interactions in this family is that between OX40 (CD134) and its partner OX40L (CD252). These molecules strongly regulate conventional CD4 and CD8 T cells, and more recent data are highlighting their ability to modulate NKT cell and NK cell function as well as to mediate cross-talk with professional antigen-presenting cells and diverse cell types such as mast cells, smooth muscle cells, and endothelial cells. Additionally, OX40-OX40L interactions alter the differentiation and activity of regulatory T cells. Blocking OX40L has produced strong therapeutic effects in multiple animal models of autoimmune and inflammatory disease, and, in line with a prospective clinical future, reagents that stimulate OX40 signaling are showing promise as adjuvants for vaccination as well as for treatment of cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据